ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AbbVie, Harpoon expand bispecific antibody pact

by Lisa M. Jarvis
November 30, 2019 | APPEARED IN VOLUME 97, ISSUE 47

Expanding on an earlier pact, AbbVie will pay Harpoon Therapeutics $50 million for an option to license HPN217, a bispecific antibody that targets B-cell maturation antigen, and to add six targets to the firms’ existing discovery deal. Harpoon could get another $50 million when the first person is treated with HPN217 in the clinic. AbbVie will decide whether to buy global rights to the drug after a planned Phase I/II study in multiple myeloma is completed.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment